| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Director, 10% Owner | Director
3 companies
Hudson Executive Capital LP last filed a Form 4 in February 2024, as 10% Owner at TALK. The filings on record cover 3 companies.
Our model assigns Hudson Executive Capital LP a below-average insider score of 49/100, based on 10 past trades. Over a 12-month horizon, 30.0% of those trades were profitable, with an average 12-month return of -25.9%.
At the last filing, the largest reported position was 17,980,600 shares of TALK. Net of sales, the TALK filings show accumulation of 190,600 shares.
Hudson Executive Capital LP has 19 Form 4 filings on record from August 2019 to February 2024, across 3 companies: 10% Owner at Cantaloupe (CTLP), 2019–2024; 10% Owner at Talkspace (TALK), 2021; Director at Eagle Pharmaceuticals (EGRX), 2019.
The 40 reported transactions were 18 open-market sales, 17 open-market purchases, 3 stock awards and 2 other transactions.
Counted by filing, the open-market trades come to 7 purchases worth about $20.1M and 8 sales worth about $5.5M.
The largest open-market purchase was 1,801,000 shares of CTLP at an average $4.58 on September 26, 2019, about $8.2M.
The largest open-market sale was 28,038 shares of EGRX at an average $60.64 on October 15, 2019, about $1.7M.
Shares as reported in the last Form 4 for each company; the most recent is from February 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 21, 2023 | CTLP Cantaloupe, Inc. | 10% Owner | Sell | 90,582 | $6.30 | $570,666.60 | -1.0% | +11.0% | +6.6% | |
| May 25, 2022 | CTLP Cantaloupe, Inc. | - | Buy | 143,460 | $4.53 | $649,711.05 | +1.2% | +16.6% | +22.9% | |
| Dec 29, 2021 | CTLP Cantaloupe, Inc. | Director, 10% Owner | Buy | 106,635 | $8.07 | $860,198.61 | +0.9% | -15.0% | -48.1% | |
| Aug 16, 2021 | TALK Talkspace, Inc. | 10% Owner | Buy | 190,600 | $5.28 | $1,006,687.00 | +1.1% | -36.5% | -69.9% | |
| Oct 25, 2019 | EGRX Eagle Pharmaceuticals, Inc. | Director | Sell | 16,931 | $63.48 | $1,074,714.80 | -2.3% | - | - | |
| Oct 23, 2019 | EGRX Eagle Pharmaceuticals, Inc. | Director | Sell | 10,616 | $62.63 | $664,924.34 | -1.4% | - | - | |
| Oct 18, 2019 | EGRX Eagle Pharmaceuticals, Inc. | Director | Sell | 15,544 | $62.58 | $972,745.45 | -2.0% | - | - | |
| Oct 16, 2019 | CTLP Cantaloupe, Inc. | 10% Owner | Buy | 245,000 | $7.08 | $1,734,518.00 | +2.4% | - | - | |
| Oct 15, 2019 | EGRX Eagle Pharmaceuticals, Inc. | Director | Sell | 28,038 | $60.64 | $1,700,256.89 | -3.5% | - | - | |
| Oct 8, 2019 | EGRX Eagle Pharmaceuticals, Inc. | Director | Sell | 6,459 | $60.09 | $388,119.33 | -0.8% | - | - |